Institution
Canadian Blood Services
Nonprofit•Ottawa, Ontario, Canada•
About: Canadian Blood Services is a nonprofit organization based out in Ottawa, Ontario, Canada. It is known for research contribution in the topics: Platelet & Antibody. The organization has 766 authors who have published 1468 publications receiving 37934 citations.
Topics: Platelet, Antibody, Transplantation, Population, Antigen
Papers published on a yearly basis
Papers
More filters
••
TL;DR: It is suggested that PMV play an important role in tumor progression/metastasis and angiogenesis in lung cancer.
Abstract: The role of platelets in tumor progression and metastasis has been recognized but the mechanism of their action remains unclear. Five human lung cancer cell lines (A549, CRL 2066, CRL 2062, HTB 183, HTB 177) and a murine Lewis lung carcinoma (LCC) cell line (for an in vivo model of metastasis) were used to investigate how platelet-derived microvesicles (PMV), which are circular fragments shed from the surface membranes of activated platelets, and exosomes released from platelet alpha-granules, could contribute to metastatic spread. We found that PMV transferred the platelet-derived integrin CD41 to most of the lung cancer cell lines tested and stimulated the phosphorylation of mitogen-activated protein kinase p42/44 and serine/threonine kinase as well as the expression of membrane type 1-matrix metalloproteinase (MT1-MMP). PMV chemoattracted 4 of the 5 cell lines, with the highly metastatic A549 cells exhibiting the strongest response. In A549 cells, PMV were shown to stimulate proliferation, upregulate cyclin D2 expression and increase trans-Matrigel chemoinvasion. Furthermore, in these cells, PMV stimulated mRNA expression for angiogenic factors such as MMP-9, vascular endothelial growth factor, interleukin-8 and hepatocyte growth factor, as well as adhesion to fibrinogen and human umbilical vein endothelial cells. Intravenous injection of murine PMV-covered LLC cells into syngeneic mice resulted in significantly more metastatic foci in their lungs and LLC cells in bone marrow than in control animals injected with LCC cells not covered with PMV. Based on these findings, we suggest that PMV play an important role in tumor progression/metastasis and angiogenesis in lung cancer.
712 citations
••
Harvard University1, University of South Florida2, University of Washington3, University of British Columbia4, University of Ottawa5, Boston Children's Hospital6, Christiana Care Health System7, University of Minnesota8, University of Vermont9, Washington University in St. Louis10, Food and Drug Administration11, Wayne State University12, University of Pennsylvania13, Englewood Hospital and Medical Center14, Yale University15, Canadian Blood Services16, University of Massachusetts Medical School17, University of Texas Southwestern Medical Center18, Johns Hopkins University19, Children's National Medical Center20
TL;DR: These guidelines were designed to provide pragmatic recommendations, based on the best available published evidence, about when platelet transfusion may be appropriate in adult patients, and provide advice for adult patients who are candidates for platelets transfusion.
Abstract: Platelet transfusions are administered to prevent or treat bleeding in patients with quantitative or qualitative platelet disorders The AABB (formerly, the American Association of Blood Banks) dev
684 citations
••
TL;DR: In vitro results suggest that the SDF‐1‐CXCR4 and HGF‐c‐met axes, along with MMPs, may be involved in recruitment of expanded MSCs to damaged tissues.
Abstract: Human mesenchymal stem cells (MSCs) are increasingly being considered in cell-based therapeutic strategies for regeneration of various organs/tissues. However, the signals required for their homing and recruitment to injured sites are not yet fully understood. Because stromal-derived factor (SDF)-1 and hepatocyte growth factor (HGF) become up-regulated during tissue/organ damage, in this study we examined whether these factors chemoattract ex vivo-expanded MSCs derived from bone marrow (BM) and umbilical cord blood (CB). Specifically, we investigated the expression by MSCs of CXCR4 and c-met, the cognate receptors of SDF-1 and HGF, and their functionality after early and late passages of MSCs. We also determined whether MSCs express matrix metalloproteinases (MMPs), including membrane type 1 (MT1)-MMP, matrix-degrading enzymes that facilitate the trafficking of hematopoietic stem cells. We maintained expanded BM- or CB-derived MSCs for up to 15-18 passages with monitoring of the expression of 1) various tissue markers (cardiac and skeletal muscle, neural, liver, and endothelial cells), 2) functional CXCR4 and c-met, and 3) MMPs. We found that for up to 15-18 passages, both BM- and CB-derived MSCs 1) express mRNA for cardiac, muscle, neural, and liver markers, as well as the vascular endothelial (VE) marker VE-cadherin; 2) express CXCR4 and c-met receptors and are strongly attracted by SDF-1 and HGF gradients; 3) express MMP-2 and MT1-MMP transcripts and proteins; and 4) are chemo-invasive across the reconstituted basement membrane Matrigel. These in vitro results suggest that the SDF-1-CXCR4 and HGF-c-met axes, along with MMPs, may be involved in recruitment of expanded MSCs to damaged tissues.
639 citations
••
TL;DR: This commentary discusses the reasons for this, summarizes recent progress in the field and outlines what is needed to bring this technology closer to clinical application.
Abstract: 1proposed the idea of using ultrathin polymer membrane microcapsules for the immunoprotection of transplanted cells and introduced the term ‘artificial cells’ to define the concept of bioencapsulation, which was successfully implemented 20 years later to immobilize xenograft islet cells. When implanted into rats, the microencapsulated islets corrected the diabetic state for several weeks 2 . Since then, there has been considerable progress toward understanding the biological and technological requirements for successful transplantation of encapsulated cells in experimental animal models, including rodents and non-human primates. Bioencapsulation has provided a range of promising therapeutic treatments for diabetes 3 , hemophilia 4 , cancer 5 and renal failure 6 . Additionally, the functional applicability of cell encapsulation in humans has also been reported in several clinical trials 7,8
581 citations
••
TL;DR: ABT-related mortality can be further reduced by universally applying the policies of avoiding prospective donors alloimmunized to WBC antigens from donating plasma products, adopting strategies to prevent HTRs, WBC-reducing components transfused to patients undergoing cardiac surgery, and reducing exposure to allogeneic donors through conservative transfusion guidelines and avoidance of product pooling.
535 citations
Authors
Showing all 769 results
Name | H-index | Papers | Citations |
---|---|---|---|
Stephen J. O'Brien | 153 | 1062 | 93025 |
James A. Russell | 124 | 1024 | 87929 |
Theodore E. Warkentin | 96 | 440 | 34706 |
Dean Fergusson | 90 | 655 | 32781 |
Dylan R. Edwards | 87 | 248 | 25324 |
Mariusz Z. Ratajczak | 84 | 525 | 27088 |
John G. Kelton | 83 | 326 | 29537 |
Paul E. Goss | 79 | 377 | 26502 |
Morris A. Blajchman | 71 | 329 | 22824 |
Mortimer Poncz | 70 | 306 | 15727 |
Hong Yang | 70 | 186 | 19253 |
Janina Ratajczak | 66 | 235 | 19136 |
Jane E. Freedman | 65 | 348 | 13704 |
Peter Nickerson | 61 | 213 | 16062 |
John Freedman | 59 | 228 | 10641 |